AngioDynamics stock slips 4% despite beating estimates on Med Tech growth

Investing.com -- On Wednesday, AngioDynamics Inc. (NASDAQ: ANGO) reported first quarter fiscal 2027 results that exceeded analyst expectations, with adjusted loss per share of -$0.04 compared to the consensus estimate of -$0.11 and revenue of $80.9 million versus the estimate of $80.5 million.

Shares of the medical technology company slid down -4.26% in pre-market trading following the release.

The company’s revenue increased 6.9% YoY, driven by its Med Tech segment, which grew 13.2% to $39.9 million. This marked the eighth consecutive quarter of double-digit Med Tech growth. The Med Device segment posted $41.0 million in sales, up 1.4% YoY. Gross margin expanded 410 basis points to 59.4%, though this included a benefit from tariff refunds received during the quarter.

"Our first quarter results reflect the continued, consistent execution we’ve built into this business," said Jim Clemmer, President and Chief Executive Officer. "Med Tech again led our growth, highlighted by Auryon’s 21st consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform."

Within Med Tech, Auryon sales grew 14.7% to $18.9 million, while Mechanical Thrombectomy delivered $12.0 million in sales, up 6.7%. NanoKnife sales surged 29.0% to $8.3 million, driven by demand for prostate procedures.

The company reported a GAAP net loss of $7.1 million, or -$0.17 per share, compared to a loss of $10.9 million, or -$0.26 per share, in the prior year quarter. Adjusted EBITDA improved to $5.0 million from $2.2 million a year ago.

AngioDynamics reiterated its fiscal 2027 guidance, projecting revenue of $336 million to $341 million versus the consensus of $337.32 million. The midpoint of $338.5 million is slightly above the analyst estimate. The company expects adjusted EPS of -$0.29 to -$0.24, with a midpoint of -$0.265.

The company also announced that Eric Honroth will become President and Chief Executive Officer effective November 2, 2026, succeeding Clemmer, who is retiring after ten years.

Original Article

You May Also Be Interested In

• AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance
• Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
• MicroVision stock tumbles on reiterated 2026 guidance